Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 134, Issue 7

August 15 2019

In this Issue

BLOOD COMMENTARY
PLENARY PAPER
BLOOD SPOTLIGHT
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
THROMBOSIS AND HEMOSTASIS
BLOOD WORK
RETRACTION
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

BLOOD COMMENTARY

IMMUNOBIOLOGY AND IMMUNOTHERAPY

The case for CAR T-cell therapy in follicular lymphomas

Michael R. Bishop

View Articletitled, The case for CAR T-cell therapy in follicular lymphomas

PLENARY PAPER

Red Cells, Iron, and Erythropoiesis

Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD

Yunfeng Liu,Hui Zhong,Weili Bao,Avital Mendelson,Xiuli An,Patricia Shi,Stella T. Chou,Deepa Manwani,Karina Yazdanbakhsh

View Articletitled, Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD

Supplemental data

BLOOD SPOTLIGHT

An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma

Paul G. Murray,Lawrence S. Young

View Articletitled, An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma

REVIEW ARTICLE

The simpler, the better: oral arsenic for acute promyelocytic leukemia
CME Clinical Trials & Observations

Hong-Hu Zhu,Jiong Hu,Francesco Lo-Coco,Jie Jin

View Articletitled, The simpler, the better: oral arsenic for acute promyelocytic leukemia

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Clinical Trials & Observations

Jeremy S. Abramson,Jon E. Arnason,Ann S. LaCasce,Robert Redd,Jeffrey A. Barnes,Lubomir Sokol,Robin Joyce,David Avigan,Donna Neuberg,Ronald W. Takvorian,Ephraim P. Hochberg,Celeste M. Bello

View Articletitled, Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

Supplemental data

HEMATOPOIESIS AND STEM CELLS

PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells

Tianyuan Hu,Kiyomi Morita,Matthew C. Hill,Yajian Jiang,Ayumi Kitano,Yusuke Saito,Feng Wang,Xizeng Mao,Kevin A. Hoegenauer,Kazuhiro Morishita,James F. Martin,P. Andrew Futreal,Koichi Takahashi,Daisuke Nakada

View Articletitled, PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Clinical Trials & Observations

Craig S. Sauter,Brigitte Senechal,Isabelle Rivière,Ai Ni,Yvette Bernal,Xiuyan Wang,Terence Purdon,Malloury Hall,Ashvin N. Singh,Victoria Z. Szenes,Sarah Yoo,Ahmet Dogan,Yongzeng Wang,Craig H. Moskowitz,Sergio Giralt,Matthew J. Matasar,Miguel-Angel Perales,Kevin J. Curran,Jae Park,Michel Sadelain,Renier J. Brentjens

View Articletitled, CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma

Supplemental data

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Clinical Trials & Observations Brief Report

Alexandre V. Hirayama,Jordan Gauthier,Kevin A. Hay,Jenna M. Voutsinas,Qian Wu,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Stanley R. Riddell,David G. Maloney,Cameron J. Turtle

View Articletitled, High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy

LYMPHOID NEOPLASIA

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Brief Report

Anne Quinquenel,Luc-Matthieu Fornecker,Rémi Letestu,Loïc Ysebaert,Carole Fleury,Grégory Lazarian,Marie-Sarah Dilhuydy,Delphine Nollet,Romain Guieze,Pierre Feugier,Damien Roos-Weil,Lise Willems,Anne-Sophie Michallet,Alain Delmer,Katia Hormigos,Vincent Levy,Florence Cymbalista,Fanny Baran-Marszak,on behalf of the French Innovative Leukemia Organization (FILO) CLL Group

View Articletitled, Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Supplemental data

THROMBOSIS AND HEMOSTASIS

Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity

Jue Wang,Usha R. Pendurthi,L. Vijaya Mohan Rao

View Articletitled, Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity

Supplemental data

BLOOD WORK

Never judge a book by its cover: these neutrophils are not reactive!

Jean-Baptiste Rieu,Francois Vergez

View Articletitled, Never judge a book by its cover: these neutrophils are not reactive!

Oxidative hemolysis due to Wilson disease

Zhaodong Xu,Brian R. Berry

View Articletitled, Oxidative hemolysis due to Wilson disease

RETRACTION

Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.

View Articletitled, Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Oral arsenic for acute promyelocytic leukemia
CME

View Articletitled, Oral arsenic for acute promyelocytic leukemia

Cover Image

Cover Image

Hematoxylin and eosin–stained liver tissue of a Townes sickle cell mouse with selective depletion of patrolling monocytes by treatment with a low dose of liposome-encapsulated clodronate. Notice the vascular stasis and infarcts. See the article by Liu et al on page 579.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Chronic graft-versus-host disease: Unresolved complication or ancient history?

Aptamer BT200 blocks interaction of K1405-1408 in the VWF-A1 domain with macrophage LRP1

Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation - a National Multicenter Study

Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence

Blood coagulation factor IX: structural insights impacting hemophilia B therapy

Advertisement intended for health care professionals

Table of Contents

BLOOD COMMENTARY

The case for CAR T-cell therapy in follicular lymphomas

PLENARY PAPER

Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD

BLOOD SPOTLIGHT

An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma

REVIEW ARTICLE

The simpler, the better: oral arsenic for acute promyelocytic leukemia
CME Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Clinical Trials & Observations

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Clinical Trials & Observations Brief Report

LYMPHOID NEOPLASIA

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Brief Report

THROMBOSIS AND HEMOSTASIS

Acid sphingomyelinase plays a critical role in LPS- and cytokine-induced tissue factor procoagulant activity

BLOOD WORK

Never judge a book by its cover: these neutrophils are not reactive!

Oxidative hemolysis due to Wilson disease

RETRACTION

Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Oral arsenic for acute promyelocytic leukemia
CME

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

BLOOD COMMENTARY

PLENARY PAPER

BLOOD SPOTLIGHT

REVIEW ARTICLE

The simpler, the better: oral arsenic for acute promyelocytic leukemia CME Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma Clinical Trials & Observations

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy Clinical Trials & Observations Brief Report

LYMPHOID NEOPLASIA

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study Brief Report

THROMBOSIS AND HEMOSTASIS

BLOOD WORK

RETRACTION

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

Oral arsenic for acute promyelocytic leukemia CME

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

The simpler, the better: oral arsenic for acute promyelocytic leukemia
CME Clinical Trials & Observations

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Clinical Trials & Observations

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Clinical Trials & Observations

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Clinical Trials & Observations Brief Report

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
Brief Report

Oral arsenic for acute promyelocytic leukemia
CME